Transforming growth factor-B (TGF-B) is a potent immunosuppressant. Overproduction of TGF-B by tumor cells leads to evasion of host immune surveillance and tumor progression. Results of our early studies showed that adoptive transfer of tumor-reactive, TGF-B-insensitive CD8 + T cells into immunocompetent mice was able to eradicate lung metastasis of mouse prostate cancer. The present study was conducted with three objectives. À/À mice, tumor-reactive, TGF-B-insensitive CD8 + T cells (1.5 Â 10 7 ) were transferred with and without the cotransfer of an equal number of CD8-depleted splenocytes from C57BL/6 donors. Naive CD8 + T cells or green fluorescent protein-empty vectortransfected tumor-reactive CD8 + T cells were transferred as controls. Forty days following the transfer, the average tumor weight in animals that received cotransfer of tumorreactive, TGF-B-insensitive CD8 + T cells and CD8-depleted splenocytes was at least 50% less than that in animals of all other groups (P < 0.05). Tumors in animals of the former group showed a massive infiltration of CD8 + T cells. This was associated with secretion of relevant cytokines, decreased tumor proliferation, reduced angiogenesis, and increased tumor apoptosis. Based on these results, we postulated a concept of antitumor immune response cycle in tumor immunology.